during exercise in chronic fatigue syndrome.
Journal: Scand J Med Sci Sports. 2009 Apr 13. [Epub ahead of print]
Authors: Robinson M, Gray SR, Watson MS, Kennedy G, Hill A, Belch JJ, Nimmo MA.
Affiliation: Strathclyde Institute of Pharmacy and Biomedical
Sciences, University of Strathclyde, Glasgow, UK.
NLM Citation: PMID: 19422646
The aim of the current study was to investigate the levels of
interleukin-6 (IL-6), its soluble receptors (sIL-6R and sgp130) and
F(2)-isoprostanes, at rest and during exercise, in patients with
chronic fatigue syndrome (CFS).
Six male CFS patients and six healthy controls performed an
incremental exercise test to exhaustion and a submaximal exercise
bout to exhaustion. Blood samples taken in the submaximal test at
rest, immediately post-exercise and 24 h post-exercise were analyzed
for IL-6, sIL-6R, sgp130 and F(2)-isoprostanes. A further 33 CFS and
33 healthy control participants gave a resting blood sample for IL-6
and sIL-6R measurement.
During the incremental exercise test only power output at the lactate
threshold was lower (P<0.05) in the CFS group. F(2)-isoprostanes were
higher (P<0.05) in CFS patients at rest and this difference persisted
immediately and 24 h post-exercise. The exercise study found no
differences in IL-6, sIL-6R or sgp130 at any time point between
groups. In the larger resting group, there were no differences in
IL-6 and sIL-6R between CFS and control groups.
This investigation has demonstrated that patients with CFS do not
have altered plasma levels of IL-6, sIL-6R or sgp130 either at rest
or following exercise. F(2)-isoprostanes, however, were consistently
higher in CFS patients.